| Symbol | DFTX |
|---|---|
| Name | DEFINIUM THERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Medicinal Chemicals & Botanical Products |
| Address | ONE WORLD TRADE CENTER, NEW YORK, NY 10007 |
| Telephone | 212-220-6633 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001813814 |
| Description | None |
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Read moreDefinium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Read moreNew Form DEFA14A - Definium Therapeutics, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001193125-26-182066 <b>Size:</b> 3 MB
Read moreDefinium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
Read moreDefinium Therapeutics to Participate at Upcoming Investor Conferences and Events
Read moreNew Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
Read moreKarlin Daniel 🔴 sold 8.0K shares of Definium Therapeutics, Inc. (DFTX) at $18.47 Transaction Date: Mar 25, 2026 | Filing ID: 126830
Read moreSullivan Mark 🔴 sold 10.7K shares of Definium Therapeutics, Inc. (DFTX) at $18.47 Transaction Date: Mar 25, 2026 | Filing ID: 126827
Read more